Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 16/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 16/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 16/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 16/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 16/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 16/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979190 | 0.84 | PSEN1 (0.48) | ELOVL1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14263409 | 0.82 | CES2 (0.46) | ELOVL1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20241935 | 0.78 | HDAC4 (0.57) | ELOVL1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL28296820 | 0.77 | PSEN1 (0.49) | ELOVL1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18742469 | 0.76 | HDAC4 (0.46) | ELOVL1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4811086 | 0.73 | HDAC4 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17508231 | 0.73 | HSD11B1 (0.46) | — | |
| SCHEMBL21051848 | 0.73 | AKR1C3 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21051840 | 0.72 | HDAC4 (0.39) | HDAC4 | |
| SCHEMBL4962846 | 0.72 | DGAT1 (0.42) | HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004142-A1 | Chemical compounds | TIE1, KDR, TEK | ELOVL1 2987/4885PSEN1 2600/4885PSEN2 1266/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | ELOVL1 3790/4885PSEN1 2399/4885PSEN2 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.